Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|8|2|78-85

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.8, Iss.2, 2015-08, pp. : 78-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 33-43

Bentham Science Publishers

Access to resources Recommend Favorite

Theranostic Applications of Lutetium-177 in Radionuclide Therapy

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 94-101

Bentham Science Publishers

Access to resources Recommend Favorite

Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 19-32

Bentham Science Publishers

Access to resources Recommend Favorite

Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 95-106

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 6-7

Bentham Science Publishers

Access to resources Recommend Favorite